Xie B, Chen S, Xu Y, Han W, Hu R, Chen M, et al

1300-C A 20% DECREASE OF SERUM CHI3L1 INDICATES HISTOLOGICAL REGRESSION IN PATIENTS WITH CHRONIC HEPATITIS B DURING ANTIVIRAL TREATMENT Tongtong Meng 1 , Lin Wang 1 , Jialing Zhou 1 , Biaoyang Lin 2 , Yameng Sun 1 , Bingqiong Wang 1 , Shuyan Chen 3 , Xiaojuan Ou 1 , Jidong Jia 1 , Hong You 3 and Xiaoning Wu 1 , (1)Liver Research Center, Beijing Friendship Hospital, Capital Medical University, National Clinical Research Center of Digestive Diseases, Beijing, China, (2)Zhejiang California International Nanosystems Institute (ZCNI) Proprium Research Center, Zhejiang University, Hangzhou Proprium Biotech Company Limited, Hangzhou, China, (3)Liver Research Center, Beijing Friendship Hospital, Capital Medical University Background: Chitinase 3-like 1 (CHI3L1) is a marker for staging of liver fibrosis, however its dynamic change and the potential application of CHI3L1 as a non-invasive surrogate marker for liver fibrosis regression in patients with chronic hepatitis B (CHB) during antiviral treatment is unknown

Why Conventional Oral Glutathione Often Falls Short Even though oral glutathione tablets and capsules are commonly used, they often deliver disappointing and inconsistent results in clinical settings, and this can be attributed to several key issues: They break down in gastric acid and through intestinal enzymes
Using more than one strategy is often helpful
No official U.S